Compare PK & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | CLDX |
|---|---|---|
| Founded | 1946 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | N/A | 2008 |
| Metric | PK | CLDX |
|---|---|---|
| Price | $11.59 | $26.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $11.55 | ★ $44.10 |
| AVG Volume (30 Days) | ★ 3.7M | 702.6K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 8.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,541,000,000.00 | $2,599,000.00 |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | $0.73 | $23.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.27 | $14.40 |
| 52 Week High | $13.90 | $30.50 |
| Indicator | PK | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 51.43 |
| Support Level | $11.13 | $25.00 |
| Resistance Level | $11.56 | $26.99 |
| Average True Range (ATR) | 0.38 | 1.19 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 79.73 | 50.46 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.